Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia.

PloS one - 1 Jan 2014

Sheehan Vivien A, Crosby Jacy R, Sabo Aniko, Mortier Nicole A, Howard Thad A, Muzny Donna M, Dugan-Perez Shannon, Aygun Banu, Nottage Kerri A, Boerwinkle Eric, Gibbs Richard A, Ware Russell E, Flanagan Jonathan M

Abstract excerpt

Hydroxyurea has proven efficacy in children and adults with sickle cell anemia (SCA), but with considerable inter-individual variability in the amount of fetal hemoglobin (HbF) produced. Sibling and twin studies indicate that some of that drug response variation is heritable. To test the hypothesis that genetic modifiers influence pharmacological induction of HbF, we investigated phenotype-genotype associations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Sickle Cell
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fetal Hemoglobin

Share to Genomics

Share to Hydroxyurea

Share to Maximum Tolerated Dose

Share to Open Reading Frames

Source

Open in PubMed Open full text

Identifiers

PMID: 25360671
DOI: 10.1371/journal.pone.0110740
PMCID: PMC4215999

Genes

SALL2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia.PMID 25360671Read ↗

Emerging science of hydroxyurea therapy for pediatric sickle cell disease.Semantic proximity Read ↗

Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.Semantic proximity Read ↗

Exploring Pharmacogenetic Factors Influencing Hydroxyurea Response in Tanzanian Sickle Cell Disease Patients: A Genomic Medicine ApproachSemantic proximity Read ↗

Exploring pharmacogenetic factors influencing hydroxyurea response in tanzanian sickle cell disease patients: a genomic medicine approach.Semantic proximity Read ↗

A replication study of novel fetal hemoglobin-associated genetic variants in sickle cell disease-only cohorts.Semantic proximity Read ↗

Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemiaSemantic proximity Read ↗

Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea.Semantic proximity Read ↗

Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea.Semantic proximity Read ↗

A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.Semantic proximity Read ↗

Optimizing hydroxyurea therapy for sickle cell anemia.Semantic proximity Read ↗

A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapySemantic proximity Read ↗

Modeling Genetic Diversity in Sickle Cell Disease Reveals Heterogeneous Responses to HbF-Inducing TherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.